General Commentary ARTICLE
Mechanism of action of acetazolamide and idiopathic intracranial hypertension
- 1Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- 2Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- 3Division of Neurology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA
A commentary on
Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial
by Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, et al. (2014). JAMA 311:1641–51. doi:10.1001/jama.2014.3312
We wish to comment on the correspondence regarding the question of efficacy and mechanism of action of acetazolamide in the treatment of idiopathic intracranial hypertension (IIH), published in JAMA September 10, 2014 (1). Whereas Sinclair et al. (2) minimize the benefits and favor a theory of weight loss as the reason for a small improvement in symptoms and reduced papilledema, Wall et al. (3) hold that acetazolamide has a direct effect on papilledema and intracranial pressure, and significantly improves visual field function in a patient with IIH. The distribution of carbonic anhydrase and acetazolamide in the brain and how that relates to the mechanism of action of acetazolamide in IIH are not addressed.
In the 1950s, a similar discussion concerned the mechanism of acetazolamide in the treatment of epileptic seizures. Initially, it was thought that the effect was indirect via the kidneys and was related to an induced metabolic acidosis. Subsequently, acetazolamide was shown to prevent seizures in nephrectomized animals; the anticonvulsant effect was independent of the effect on the kidneys and was caused by a direct inhibition of carbonic anhydrase in the brain (4).
In patients with IIH treated with acetazolamide, the inhibition of the enzyme in the choroid plexus results in a reduction of CSF production and flow. The acid–base status of the patient may also alter the distribution of acetazolamide in the CSF and brain, but its effect on the CSF flow is secondary to that mediated by the choroid plexus. Based on the pharmacology and distribution of acetazolamide and carbonic anhydrase in the brain, the theory that emphasizes the effect of acetazolamide on CSF production in IIH is most likely primary and direct, and weight loss, when recognized as a factor, is secondary and indirect, and frequently the result of toxic doses in excess of the amount needed for complete enzyme inhibition.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
1. Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA (2014) 311:1641–51. doi:10.1001/jama.2014.3312
Keywords: carbonic anhydrase, acetazolamide, idiopathic intracranial hypertension, pharmacology, papilledema
Citation: Millichap JG and Millichap JJ (2015) Mechanism of action of acetazolamide and idiopathic intracranial hypertension. Front. Neurol. 6:13. doi: 10.3389/fneur.2015.00013
Received: 20 October 2014; Paper pending published: 09 January 2015;
Accepted: 19 January 2015; Published online: 03 February 2015.
Edited by:Priya Monrad, Children’s Hospital of Wisconsin, USA
Reviewed by:Christopher Mario Inglese, Loyola University Stritch College of Medicine, USA
Copyright: © 2015 Millichap and Millichap. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.